Rising Costs of Drug-Resistant Infections
The ICMR study highlights the rising costs of treating drug-resistant infections (AMR), showing a 33.1% increase in treatment expenses compared to treatable infections. Resistant infections also result in prolonged hospital stays (23 days vs. 12 days) and higher mortality rates (29.5% vs. 20%). Treatment costs are notably higher in private hospitals, with medication expenses driving much of the cost increase. AMR creates significant financial strain on families, often requiring loans, asset sales, or lifestyle changes. To mitigate AMR, education on responsible antibiotic use, targeted therapies, and waste management by pharmaceutical companies are crucial.
If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.
